Eva K. Havrdova
Prague, PR, Czech Republic
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 247 publications
Erratum to "Assessment of T2 lesion-based disease activity volume outcomes in predicting disease progression in multiple sclerosis over 10 years" [Multiple Sclerosis and Related Disorders, Volume 67, November 2022, 104187].
Journal: Multiple sclerosis and related disorders
Published: September 07, 2026
Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: August 03, 2026
Causal effects of multiple sclerosis therapies in left-truncated registry data.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: July 21, 2026
Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study.
Journal: Neurology and therapy
Published: June 01, 2026
Summary of Research: Cognition and Employment Status of People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-Year CLARIFY-MS Study.
Journal: Neurology and therapy
Published: March 26, 2026
Longitudinal assessment of sNfL and sGFAP in severe NMOSD treated with allogeneic stem cell transplantation.
Journal: Frontiers in immunology
Published: March 17, 2026
Managing reactivation of multiple sclerosis during treatment with natalizumab.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: December 20, 2025
Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study.
Journal: Neurology and therapy
Published: December 03, 2025
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: November 05, 2025
Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.
Journal: Journal of neurology
Published: November 03, 2025
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.
Journal: Journal of neurology
Published: November 01, 2025
International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Opportunities and Challenges.
Journal: Neurology and therapy
Published: October 22, 2025
Last Updated: 09/26/2026